ABUS Arbutus Biopharma Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABUS

Price (delayed)

$4.11

Market cap

$813.15M

P/E Ratio

5.14

Dividend/share

N/A

EPS

$0.8

Enterprise value

$797.61M

?
Relative Growth: Rel. Growth: 44
Relative Strength: Rel. Strength: 38
Relative Valuation: Rel. Valuation: 94
Relative Profitability: Rel. Profitability: 100

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a ...

Highlights
ABUS's quick ratio has soared by 50% QoQ
The debt has declined by 27% year-on-year and by 7% since the previous quarter
The company's EPS fell by 4.8% QoQ
Arbutus Biopharma's net income has decreased by 4.8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.arbutusbio.com

Key stats

What are the main financial stats of ABUS

ABUS stock price

How has the Arbutus Biopharma stock price performed over time
Intraday
-0.96%
1 week
-8.26%
1 month
-19.73%
1 year
-3.97%
YTD
-14.55%
QTD
-14.02%

Financial performance

How have Arbutus Biopharma's revenue and profit performed over time
Revenue
$181.72M
Gross profit
$181.72M
Operating income
$147.03M
Net income
$153.05M
Gross margin
100%
Net margin
84.2%
The net margin has surged by 124% year-on-year
ABUS's operating margin has surged by 122% year-on-year
Arbutus Biopharma's net income has decreased by 4.8% from the previous quarter
The company's operating income fell by 4.9% QoQ

Price vs fundamentals

How does ABUS's price correlate with its fundamentals

Growth

What is Arbutus Biopharma's growth rate over time

Valuation

What is Arbutus Biopharma stock price valuation
P/E
5.14
P/B
3.14
P/S
4.47
EV/EBIT
5.21
EV/EBITDA
5.21
EV/Sales
4.39
The company's EPS fell by 4.8% QoQ
ABUS's price to book (P/B) is 59% lower than its last 4 quarters average of 7.6 and 36% lower than its 5-year quarterly average of 4.9
The price to sales (P/S) is 88% lower than the 5-year quarterly average of 38.6 and 87% lower than the last 4 quarters average of 33.7
Arbutus Biopharma's revenue has decreased by 5% QoQ

Efficiency

How efficient is Arbutus Biopharma business performance
The company's return on sales has surged by 124% YoY
The ROIC has declined by 32% since the previous quarter
The ROE is down by 30% since the previous quarter
Arbutus Biopharma's return on assets has decreased by 27% QoQ

Dividends

What is ABUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABUS.

Financial health

How did Arbutus Biopharma financials performed over time
The company's total assets has surged by 165% YoY
ABUS's quick ratio has soared by 50% QoQ
The debt is 99% smaller than the equity
ABUS's debt to equity has dropped by 83% year-on-year and by 50% since the previous quarter
The debt has declined by 27% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.